A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy
To assess the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who do not progress after first-line chemoradiotherapy. Based on the incidence and severity of benign and serious adverse events, as well as abnormal laboratory
Limited Stage Small Cell Lung Cancer|Not Progressed After First-line Chemoradiotherapy
DRUG: TQB2450 Injection + Anlotinib Hydrochloride Capsules
Adverse event, Incidence and severity of adverse events, Start from the first dose until the last dose to within 84 days after the last dose or start new target indication treatment (whichever occurs first)|serious adverse event, Incidence and Severity of Serious Adverse Events, Start from the first dose until the last dose to within 84 days after the last dose or start new target indication treatment (whichever occurs first)
Overall response rate (ORR), ORR:According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment., Up to approximately 36 months|disease control rate, The percentage of patients who have achieved remission or stable changes in their condition after treatment compared to the evaluable cases, Up to approximately 36 months|duration of remission, The time from the first assessment of the tumor as CR or PR to the first assessment as PD (Progressive Disease) or death from any cause, Up to approximately 36 months
To assess the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who do not progress after first-line chemoradiotherapy. Based on the incidence and severity of benign and serious adverse events, as well as abnormal laboratory